ONCBeOne MedicinesSigning up patients
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Chronic Lymphocytic Leukemia · CLL · Mantle Cell Lymphoma · MCL
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 1/2
- Patients
- 258 (planned)
- Started
- Jan 23, 2025
- Main results expected
- Nov 30, 2029
- Fully finished
- Nov 30, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants who Experience Tumor Lysis Syndrome (TLS)
Measured over: Up to approximately 4 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06697184 · record last updated 2026-10-26 · checked 2026-11-09 15:47 UTC